Edwards Lifesciences stock gains 4 percent as CMS decision underpins growth story
Published on 09/17/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edwards Lifesciences stock (ISIN US28176E1082) closed at USD 89.19 on the NYSE on September 16, 2026, marking an intraday gain of about 4.0 percent that put the shares among the strongest performers in the S&P 500 that day.
Stock jumps on technical rebound and sector optimism
According to Ainvest on September 16, 2026, Edwards Lifesciences stock surged 4.02 percent to USD 89.19, rebounding from an open at USD 85.67 and reaching an intraday high of USD 89.70 as buyers stepped in at oversold technical levels.
As Trefis reported on September 17, 2026, the stock’s 4.1 percent gain on the last trading day left Edwards Lifesciences ahead of the S&P 500, where the index showed a far smaller move, and contributed to a year-to-date return of 4.7 percent for the company.
CMS TAVR coverage and TMTT growth frame the fundamental story
Beyond the short-term price action, investors are focusing on structural heart growth drivers that management has recently emphasized. According to MarketBeat on September 17, 2026, Chief Executive Officer Bernard Zovighian highlighted that Edwards Lifesciences sees its transcatheter mitral and tricuspid therapies business on track for roughly USD 250 million in revenue in 2026, with approximately 40 percent growth in that segment versus the prior year.
In the same discussion, MarketBeat reported that Zovighian described the recent Centers for Medicare and Medicaid Services National Coverage Determination for transcatheter aortic valve replacement as a positive development, noting that CMS concluded the therapy is reasonable and necessary after years of clinical evidence, which supports broader patient access and reinforces Edwards Lifesciences’ core TAVR franchise.
Management also pointed to the PROGRESS trial in moderate aortic stenosis, with results expected in approximately six weeks at the TCT meeting, according to MarketBeat on September 17, 2026, giving investors a near-term clinical catalyst that could influence expectations for future valve procedure volumes.
Analyst stance and risk considerations
Edwards Lifesciences currently carries a Moderate Buy rating among analysts, according to MarketBeat on September 17, 2026, reflecting a generally constructive but not unanimously bullish view on the shares.
At the same time, the company’s focus on transcatheter therapies such as PASCAL, EVOQUE and SAPIEN M3 in mitral and tricuspid regurgitation implies execution and regulatory risks, as approvals and adoption rates must keep pace with the growth trajectory management outlined, a point underscored in the structural heart strategy discussion summarized by MarketBeat.
Stock remains below 52-week high after latest move
Per Ainvest on September 16, 2026, traders are watching resistance around USD 90.69, with potential upside toward the 52-week high of USD 96.29 if support levels near USD 85.50 hold; measured against that range, the latest close near USD 89.19 leaves the stock several dollars below its 52-week peak while still comfortably above recent lows.
On September 16, 2026, Edwards Lifesciences shares closed at USD 89.19 on the NYSE, with the move placing the company among the top S&P 500 gainers highlighted in global market overviews from outlets such as The Economic Times, and leaving the stock’s year-to-date performance modestly positive in comparison with broader US equity benchmarks.
Edwards Lifesciences stock snapshot
- Company: Edwards Lifesciences Corporation
- ISIN: US28176E1082
- Ticker: EW
- Trading venue: NYSE
- Price (as of September 16, 2026): 89.19 USD
- Market capitalization: [value] USD (as of September 16, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
